FDA label
What is Steglatro used for?
Steglatro contains ertugliflozin pidolate. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “STEGLATRO® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Steglatro?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Steglatro, tablet, film coated
Indications and Usage, quoted from the label by Merck Sharp & Dohme LLC (NDA209803). Cross-references to other label sections are left out.
STEGLATRO® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Limitations of Use
- Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus.
Source: DailyMed label, set id e6f3e718-bb99-48f1-ab94-b9f0af05fed6, version 17, effective June 3, 2026. NDC 0006-5363, one of 2 listings for this product.
Questions
What is Steglatro used for?
The FDA label says: “STEGLATRO® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.”
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.